Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant
暂无分享,去创建一个
D. Marin | E. Shpall | U. Popat | M. Qazilbash | A. Alousi | R. Champlin | T. Soones | R. Mehta | C. Hosing | P. Kebriaei | B. Oran | A. Olson | S. Srour | R. Saliba | A. Gulbis | R. C. Fontillas | Rachel Ombres | Jill B Ferguson | Nicholas Szewczyk | An T Ngo-Huang | Latoya M. Adekoya | Richard Lindsay | Z. Rivera
[1] D. Marin,et al. Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. , 2021, Transplantation and cellular therapy.
[2] M. Pasquini,et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. , 2020, Blood advances.
[3] N. Kröger,et al. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation , 2020, Leukemia.
[4] P. Hari,et al. Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] R. Olin. Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. , 2019, Blood.
[6] P. Riedell,et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. , 2019, Blood advances.
[7] S. Montoto,et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. , 2019, The Lancet. Haematology.
[8] M. Perales,et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies , 2019, Bone Marrow Transplantation.
[9] G. Abel,et al. Gait speed, grip strength and clinical outcomes in older patients with hematologic malignancies. , 2019, Blood.
[10] L. Jones,et al. Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. , 2019, Journal of the National Cancer Institute.
[11] K. Rezvani,et al. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. , 2018, The Lancet. Haematology.
[12] W. Wood,et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. , 2017, Blood.
[13] M. Elzimaity,et al. Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival , 2017, Supportive Care in Cancer.
[14] M. Pasquini,et al. Current use and trends in hematopoietic cell transplantation , 2017 .
[15] Tetsuji Yamamoto,et al. Clinical impact of sarcopenia and relevance of nutritional intake in patients before and after allogeneic hematopoietic stem cell transplantation , 2017, Journal of Cancer Research and Clinical Oncology.
[16] Bradford J. Kim,et al. The Impact of Postoperative Complications on a Timely Return to Intended Oncologic Therapy (RIOT): the Role of Enhanced Recovery in the Cancer Journey , 2016, International anesthesiology clinics.
[17] S. Bhatia,et al. Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients , 2015 .
[18] K. Domen,et al. Balance function in patients who had undergone allogeneic hematopoietic stem cell transplantation. , 2015, Gait & posture.
[19] M. Sorror,et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] S. Mohile,et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. , 2014, Journal of geriatric oncology.
[21] K. Gaensler,et al. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. , 2014, Journal of geriatric oncology.
[22] O. Ljungqvist. ERAS--enhanced recovery after surgery: moving evidence-based perioperative care to practice. , 2014, JPEN. Journal of parenteral and enteral nutrition.
[23] R. Stauder,et al. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.
[24] K. van Besien,et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] K. Domen,et al. Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation , 2012, Supportive Care in Cancer.
[26] K. Domen,et al. Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation , 2012, Supportive Care in Cancer.
[27] P. Hari,et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.
[28] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[29] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.